1513.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 11:08):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	297 300
Vidutinė apimtis	674 076
Rinkos kapitalizacija	33.58B
EPS	HKD0.650 ( Q1 \| 2024-03-31 )
Kita pelno data	( HKD0.603 ) 2024-08-22
Last Dividend	HKD1.744 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	11.22 (Sector) 14.27 (Industry) 0
ATR14	HKD0.0300 (0.12%)

0013.HK -0.72%

0239.HK 1.24%

0455.HK 1.96%

0512.HK -0.21%

0570.HK 0.83%

0719.HK 0.75%

0858.HK 2.56%

0867.HK 0.76%

0874.HK 0.24%

0911.HK -1.75%

1011.HK -10.26%

1312.HK 3.03%

1349.HK 0.56%

1498.HK 0.00%

1513.HK 0.78%

1558.HK 5.15%

1652.HK -2.02%

1681.HK 2.58%

2161.HK 5.00%

2196.HK 0.46%

2552.HK 2.70%

2633.HK 1.56%

2877.HK -1.79%

3737.HK 0.00%

6185.HK 0.72%

6896.HK -0.65%

8049.HK -0.76%

8329.HK 3.62%

8622.HK 0.00%

9989.HK 2.52%

Koreliacija (AI algo v.1.1b): Undervalued: 0.03% HKD25.71 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: 0.55 (weak)

Signal:(55.213) Neutral

Livzon Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Livzon Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.35
( neutral )

-0.65
( moderate negative )

0.00
( neutral )

-0.10
( neutral )

0.00
( neutral )

-0.55
( weak negative )

Livzon Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	HKD12.43B
Bruto pelnas:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2023
Pajamos:	HKD12.43B
Bruto pelnas:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2022
Pajamos:	HKD12.63B
Bruto pelnas:	HKD8.17B (64.68 %)
EPS:	HKD2.04

FY	2021
Pajamos:	HKD12.06B
Bruto pelnas:	HKD7.81B (64.75 %)
EPS:	HKD1.900

Financial Reports:

No articles found.

Livzon Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD1.744 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Livzon Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.98 - good (99.81%) | Divividend Growth Potential Score: 6.03 - Stable (20.65%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.221	2014-07-08
Last Dividend	HKD1.744	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	HKD9.31	--
Avg. Dividend % Per Year	0.00%	--
Score	3	--
Div. Sustainability Score	9.98
Div.Growth Potential Score	6.03
Div. Directional Score	8.01	--

Next Divdend (Est)
(2025-06-16)

HKD1.912 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
04 Jul 2023	HKD1.744	30 Nov -0001	30 Nov -0001	30 Nov -0001
30 May 2022	HKD1.512	30 Nov -0001	30 Nov -0001	30 Nov -0001
01 Jun 2021	HKD1.506	30 Nov -0001	30 Nov -0001	30 Nov -0001
04 Jun 2020	HKD1.253	30 Nov -0001	30 Nov -0001	30 Nov -0001
03 Jul 2019	HKD1.050	30 Nov -0001	30 Nov -0001	30 Nov -0001
22 Jun 2018	HKD1.455	30 Nov -0001	30 Nov -0001	30 Nov -0001
05 Jul 2017	HKD0.260	30 Nov -0001	30 Nov -0001	30 Nov -0001
15 Jun 2016	HKD0.270	30 Nov -0001	30 Nov -0001	30 Nov -0001
02 Jul 2015	HKD0.0444	30 Nov -0001	30 Nov -0001	30 Nov -0001
08 Jul 2014	HKD0.221	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6808.HK	Ex Dividend Junior	2023-08-22	Annually	0.00%
1045.HK	Ex Dividend Knight	2023-09-18	Semi-Annually	0.00%
2342.HK	Ex Dividend Knight	2023-09-07	Annually	0.00%
0599.HK	Ex Dividend Junior	2023-09-13	Annually	0.00%
1836.HK	Ex Dividend Knight	2023-09-06	Annually	0.00%
0173.HK	Ex Dividend Junior	2023-09-12	Semi-Annually	0.00%
9999.HK	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
1277.HK	Ex Dividend Knight	2023-10-09	Semi-Annually	0.00%
3668.HK	Ex Dividend Knight	2023-09-04	Annually	0.00%
0836.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0786	1.200	7.38	8.86	[0 - 0.3]
returnOnEquityTTM	0.142	1.500	9.53	10.00	[0.1 - 1]
payoutRatioTTM	0.799	-1.000	2.01	-2.01	[0 - 1]
currentRatioTTM	2.06	0.800	4.69	3.75	[1 - 3]
quickRatioTTM	1.802	0.800	4.11	3.29	[0.8 - 2.5]
cashRatioTTM	1.338	1.500	3.68	5.52	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	24.70	1.000	1.962	1.962	[3 - 30]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.25	2.00	8.37	10.00	[0 - 20]
debtEquityRatioTTM	0.244	-1.500	9.02	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.645	1.000	2.58	2.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.206	1.000	7.88	7.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.087	1.000	5.07	5.07	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0887	-0.0709	[0.5 - 2]
Total Score				9.98

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.29	1.000	8.96	0	[1 - 100]
returnOnEquityTTM	0.142	2.50	9.70	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.25	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	7.29	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0.799	1.500	2.01	-2.01	[0 - 1]
pegRatioTTM	1.625	1.500	2.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.316	1.000	4.60	0	[0.1 - 0.5]
Total Score				6.03

Livzon Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Livzon Pharmaceutical

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.